OXC-101 treatment in pet dogs with lymphoma or haemangiosarcomaIngress
KEY POINTS- An initial pilot clinical study in dogs with a diagnosis of lymphoma or splenic haemangiosarcoma after splenectomy
- As there is no medical treatment registered in the EU for these two indications, dogs with lymphoma or HSA are treated with so-called off-label protocols based on human-registered chemotherapy. All of these have clear side effects.
- We are striving to find better treatment options for dogs, which can also help people with Non Hodgkin's Lymphoma (NHL) and/or angiosarcoma, which are currently very difficult to treat.
Project overview
Participants
More related research
Short summary
Background
As there is no medical treatment registered in the EU for these two indications, dogs with lymphoma or HSA are treated with so-called off-label protocols based on human-registered chemotherapy. All of these have clear side effects. We are striving to find better treatment options for dogs. At the same time, dogs with spontaneous tumours are similar to the human counterpart in many aspects. Therefore, the findings of this study may be valuable for humans with Non Hodgkin's lymphoma (NHL) and/or angiosarcoma which are currently very difficult to treat.
Project overview
An initial pilot clinical study in dogs with a diagnosis of lymphoma or splenic haemangiosarcoma following splenectomy.
Aim with the project
The aim is to see if the given dose of OXC-101 is safe in dogs with lymphoma and/or splenic haemangiosarcoma post operatively. In addition, measurements of signs of efficacy will be collected. Overall, the aim is to find a treatment that improves animal welfare in these tumour conditions, which cause severe suffering and short survival in companion dogs if left untreated.